Boehringer Ingelheim Begins Clinical Development of FirstInClass Treatment for Fibrotic Diseases

Boehringer Ingelheim announced today that it has launched clinical development of its firstinclass IL11 inhibitor antibody BI 765423 with a Phase 1 study NCT05658107 to assess the safety tolerability and pharmacokinetics in healthy volunteers.

Related Keywords

Singapore ,Ingelheim ,Rheinland Pfalz ,Germany ,Andrew Khoo ,Jeffrey Lu ,Linda Ruckel ,Stuart Cook ,Cliver Wood ,Reinhard Malin ,Enleofen Bio Pte ,Tanoto Foundation Professor Of Cardiovascular Medicine ,Cardiovascular Metabolic Disorders Programme At ,National Heart Centre Singapore At Singhealth ,Boehringer Ingelheim ,Academic Medical Centre ,Animal Health ,Enleofen Bio ,Corporate Senior Vice President ,Global Head ,Discovery Research ,Prof Stuart Cook ,Tanoto Foundation Professor ,Cardiovascular Medicine ,Medical Centre ,Metabolic Disorders Programme ,Human Pharma ,Sebastian Sch ,National Heart Centre Singapore ,Media Contact ,Boehringer Ingelheim Clinical Development Firstinclass Treatment Fibrotic Diseases Il11 Inhibitor Antibody Pulmonary Fibrosis Enleofen Bio Pte Ltd Infections Inflammation Autoimmune Disorders Degenerative Tumors Injury Cliver Wood Stuart Cook Cardiovascular Medicine Biopharmaceutical Biotech ,